8/3/2021 4:07:17 PM
Curis Reports Q2 Loss Per Share Of $0.12 Vs. $0.17 Last Year
6/4/2021 8:04:22 AM
Curis Reports Discussion Of Data From Phase 1/2 Study Of CA-4948 In Patients With AML And Myelodysplastic Syndromes
5/12/2021 4:02:59 PM
Curis Q1 Loss/share $0.11 Vs. Loss $0.28 Year Ago
5/12/2021 11:04:47 AM
Curis Reports Updated Data In Two Abstracts For CA-4948 Accepted For Presentation
4/19/2021 8:01:37 AM
Curis Secures FDA Orphan Drug Designation For CA-4948 For Treatment Of AML And MDS
3/16/2021 4:18:34 PM
Curis Q4 Loss/share $0.11 Vs. Loss $0.26 Year Ago
2/9/2021 8:04:15 AM
Curis Doses First Patient In Phase 1 Study Of CA-4948 With Ibrutinib In Patients With R/R Hematologic Malignancies
2/2/2021 8:05:51 AM
Curis Begins Phase 2 LUCAS Study Of CA-4948 For Anemia In Patients With Myelodysplastic Syndromes
12/14/2020 8:09:05 AM
Curis Says Closes Underwritten Public Offering Of 29.5 Mln Shares With $169.6 Mln In Gross Proceeds